Atriva Therapeutics is one of four companies to receive the Biomarker Validation Award and aims to validate a biomarker for monitoring of MEK inhibition by the clinical-stage influenza therapy ATR-002. The award will be in t Read more ...
Atriva Therapeutics Starts Clinical Development of novel Host-Targeting Antiviral ATR-002 Against Influenza
Phase I clinical trial to evaluate safety and tolerability of ATR-002 in healthy volunteers
ATR-002 expected to show high resilienc Read more ...